Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20597141 | 0.97 | ALDH1A1 (0.44) | ALDH1A1TSHRACHELMNAALOX12 | |
| Lithium Ion SCHEMBL7103420 | 0.80 | ALDH1A1 (0.41) | ALDH1A1TSHRACHELMNAALOX12 | |
| SCHEMBL307860 | 0.76 | ALDH1A1 (0.44) | ALDH1A1TSHRACHELMNAALOX12 | |
| SCHEMBL7029427 | 0.76 | TSHR (0.47) | ALDH1A1TSHRACHELMNAALOX12 | |
| SCHEMBL21810848 | 0.73 | ALDH1A1 (0.41) | ALDH1A1TSHRACHELMNAALOX12 | |
| Lithium Ion SCHEMBL4653664 | 0.73 | CA4 (0.39) | ALDH1A1TSHRACHELMNAALOX12 | |
| Lithium Ion SCHEMBL29149666 | 0.72 | ALDH1A1 (0.47) | ALDH1A1TSHRACHELMNAALOX12 | |
| Lithium Ion SCHEMBL138828 | 0.72 | ALDH1A1 (0.47) | ALDH1A1TSHRACHELMNAALOX12 | |
| Lithium Ion SCHEMBL20543346 | 0.71 | TP53 (0.38) | ALDH1A1TSHRACHELMNAALOX12 | |
| Iodide SCHEMBL6432503 | 0.69 | ALDH1A1 (0.44) | ALDH1A1TSHRACHELMNAALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1584621-B1 | A process for the preparation of tolterodine and intermediates thereof | DIPHARMA FRANCIS SRL (IT) | 2007-06-13 | — | — | EP | disclosed |
| US-7119212-B2 | Process for the preparation of tolterodine and intermediates thereof | DIPHARMA S.P.A. (IT) | 2006-10-10 | — | — | US | disclosed |
| EP-1584621-A1 | A process for the preparation of tolterodine and intermediates thereof | Dipharma S.p.A. (IT) | 2005-10-12 | — | — | EP | disclosed |
| US-20050222437-A1 | Process for the preparation of tolterodine and intermediates thereof | DIPHARMA S.P.A. (IT) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222437-A1 | Process for the preparation of tolterodine and intermediates thereof | CYP2B6, UGT1A6, CYP2D6 | ALDH1A1 1277/4885TSHR 132/4885ACHE 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.